Onxeo SA (0NWK.L)
| Previous close | 0.0000 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.0000 - 0.0000 |
| 52-week range | |
| Volume | |
| Avg. volume | N/A |
| Market cap | 24.127M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | 42.70 |
| EPS (TTM) | 0.0100 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Onxeo Announces its Financial Agenda for 2023
PARIS, January 27, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today announced its financial agenda for 2023.
- Business Wire
ONXEO Provides Update on the Development Program For Its First-in-class Drug Candidate AsiDNATM
PARIS, January 25, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX) (Paris:ALONX), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative tumor specific drugs targeting tumor DNA Damage Response (DDR) and driver oncogenes, today provides an update on the clinical development program of its first-in-class drug candidate AsiDNATM.
- Business Wire
Onxeo: Extraordinary General Meeting of February 6, 2023: Availability of Preparatory Documents
PARIS, January 18, 2023--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX), hereafter "Onxeo" or the "Company", a clinical stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA damage response (DDR) mechanisms to fight rare or resistant cancers, today announces the availability of the preparatory documents for its Extraordinary General Meeting which will be held on Monday, February 6, 2023 at 2:00 p.m. at the Renaissance Paris Nobel Tour Eif
